P0804: Morning administration of biologic therapy is associated with decreased risk of treatment failure in patients with Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Odeyemi, I.(1,2,3)*;Baum, K.(1,2,3,4);Colombel, J.F.(5);Hirten, R.P.(2,3,5);Ungaro, R.C.(5);Renard, B.Y.(1,2,3);Ibing, S.(1,2,3);
(1)Hasso Plattner Institute- University of Potsdam, Digital Engineering Faculty, Potsdam, Germany;(2)Icahn School of Medicine at Mount Sinai, Windreich Deptartment of Artificial Intelligence & Human Health, New York, United States;(3)Icahn School of Medicine at Mount Sinai, Hasso Plattner Institute for Digital Health at Mount Sinai, New York, United States;(4)Free University Berlin, Department of Mathematics and Computer Science, Berlin, Germany;(5)Icahn School of Medicine at Mount Sinai- The Dr. Henry D. Janowitz Division of Gastroenterology, Department of Medicine, New York, United States;
1. Roda G, Jharap B, Neeraj N, Colombel JF. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol. 2016;7(1):e135. doi:10.1038/ctg.2015.63
2. Lee Y, Field JM, Sehgal A. Circadian Rhythms, Disease and Chronotherapy. J Biol Rhythms. 2021;36(6):503-531. doi:10.1177/07487304211044301
3. Diamantopoulou Z, Gvozdenovic A, Aceto N. A new time dimension in the fight against metastasis. Trends Cell Biol. 2023;33(9):736-748. doi:10.1016/j.tcb.2023.02.002
4. Swanson GR, Biglin M, Raff H, et al. Impact of Chronotherapy on 6-Mercaptopurine Metabolites in Inflammatory Bowel Disease: A Pilot Crossover Trial. Clin Transl Gastroenterol. 2023;14(2):e00549. doi:10.14309/ctg.0000000000000549
P0805: Sigmoidoscopy is sufficient as a surveillance tool in pediatric Ulcerative Colitis; full colonoscopy is not typically neededECCO'25Year: 2025
Authors: Yuval Bar-Asher , S.(1);Lev-Tzion , R.(1);Orlanski-Meyer , E.(1);Ledder , O.(1);Shteyer , E.(1);Shamasneh , I.(1);Yogev , D.(1);Assa , A.(1);Baldassano , R.N.(2);Griffiths , A.M.(3);Turner , D.(1)*;
(1)Shaare Zedek Medical Center, The Juliet Keidan Institute of Paediatric Gastroenterology Hepatology and Nutrition, Jerusalem, Israel;(2)The Children's Hospital of Philadelphia, Division of Gastroenterology- Hepatology- and Nutrition, Philadelphia, United States;(3)Hospital for Sick Children- University of Toronto, Department of Gastroenterology, Toronto, Canada;
P0806: Monitoring of vedolizumab therapy using fecal calprotectin, abdominal ultrasound, and drug levels in ulcerative colitis: a predictive algorithmECCO'25Year: 2025
Authors: HelwigPD, U.(1,2)*;Sobotzk, C.(3);Plachta- Danielzik, S.(4);Schreiber, S.(2);
(1)Internistische Praxisgemeinschaft Oldenburg, Gastroenterologie, Oldenburg, Germany;(2)University of Kiel, Gastroenterology, Kiel, Germany;(3)Kompetenznetz Darmerkrankungen, Statistik, Kiel, Germany;(4)Kompetenznetz Darmerkrankungen, Studien, Kiel, Germany;
P0807: Impact of Risankizumab on Patient-reported Outcomes and Biomarkers Over Time: Post-Hoc Analysis of Phase 2b/3 INSPIRE and COMMAND Studies in Ulcerative ColitisECCO'25Year: 2025
Authors: Lindsay, J.(1)*;Ferrante, M.(2);Armuzzi, A.(3);Peyrin-Biroulet, L.(4);Dubinsky, M.C.(5);Danese, S.(6);Garrison, A.(7);Yafei, Z.(7);Kalabic, J.(7);Remple, V.(7);Vladea, R.(7);Sharma, D.(7);Panaccione, R.(8);
(1)Royal London Hospital- Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)IRCCS Humanitas Research Hospital- Humanitas University, Inflammatory Bowel Disease Center, Milan, Italy;(4)Nancy University Hospital, Gastroenterology Department and Inserm U954, Vandœuvre-lès-Nancy, France;(5)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(6)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milano, Italy;(7)AbbVie Inc., Gastroenterology, North Chicago, United States;(8)University of Calgary, Inflammatory Bowel Disease Clinic, Calgary, Canada;
P0808: Early Top-down treatment improves transmural remission rates in Crohn's disease - a risk-adjusted propensity score matched analysisECCO'25Year: 2025
Authors: Fernandes, S.R.(1)*;Rodrigues, I.B.C.(1);Da Silva Neves, A.(1);Saraiva, S.(1);Rita Gonçalves, A.(1);Valente, A.(1);Moura Santos, P.(1);Correia, L.(1);Cortez-Pinto, H.(1);Magro, F.(2);
(1)Unidade Local de Saúde de Santa Maria, Serviço de Gastrenterologia e Hepatologia, Lisbon, Portugal;(2)Faculty of Medicine- University of Porto, Cintesis@Rise, Porto, Portugal; Grupo de Estudos de Doenças Inflamatórias do Intestino
P0809: Higher Ustekinumab Concentrations in Induction are associated With Better Endoscopic Outcomes in Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Serra-Ruiz, X.(1)*;Céspedes-Martínez, E.(1);Mayorga Ayala, L.(1);Herrera de Guise, C.(1);Robles, V.(1);Lastiri, E.(1);Garcia-Garcia, S.(2);Larrosa-García, M.(2);Sanz Martínez, M.T.(3);Pérez Martínez, Z.(1);Oller, E.(1);Borruel, N.(1);
(1)Hospital Universitari Vall d'Hebron, Crohn's and Colitis Attention Unit- Gastroenterology Department, Barcelona, Spain;(2)Hospital Universitari Vall d'Hebron, Pharmacy Department, Barcelona, Spain;(3)Hospital Universitari Vall d'Hebron, Immunology Department, Barcelona, Spain;
K. Papamichael, E.H. Vogelzang, J. Lambert, G. Wolbink, A.S. Cheifetz, Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases, Expert Rev Clin Immunol 15 (2019) 837–848. https://doi.org/10.1080/1744666X.2019.1630273.
D. Alsoud, G. De Hertogh, G. Compernolle, S. Tops, J. Sabino, M. Ferrante, D. Thomas, S. Vermeire, B. Verstockt, Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis, J Crohns Colitis 16 (2022) 1562–1570. https://doi.org/10.1093/ECCO-JCC/JJAC067.
C. Mcdonald, H. Kerr, E. Gibbons, T. Lukose, D. Cheriyan, G. Harewood, S. Patchett, A. O’toole, O. Kelly, K. Boland, Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn’s Disease: An Experience of 2 IBD Centers, Inflamm Bowel Dis 30 (2024) 423–428. https://doi.org/10.1093/ibd/izad073.
T. Straatmijer, V.B.C. Biemans, D.J.A.R. Moes, F. Hoentjen, R. ter Heine, P.W.J. Maljaars, R. Theeuwen, M. Pierik, M. Duijvestein, A.E. van der Meulen-de Jong, Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease, Dig Dis Sci 68 (2023) 2647. https://doi.org/10.1007/S10620-023-07822-7.
P0810: Anti TNF Treatment is Associated with Reduced Risk of Diabetes in Patients With Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Shafrir, A.(1)*;Stokar, J.(2);Rubin, D.T.(1);
(1)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(2)Faculty of Medicine- Hebrew University of Jerusalem- - Hadassah Medical Center, Department of Endocrinology, Jerusalem, Israel;
1 Knobler, Hilla MD; Zhornicky, Taiba MD; Sandler, Alex MD; Haran, Nurit PhD; Ashur, Yafa MD; Schattner, Ami MD. Tumor Necrosis Factor–α–Induced Insulin Resistance May Mediate The Hepatitis C Virus–Diabetes Association. American Journal of Gastroenterology 98(12):p 2751-2756, December 2003. | DOI: 10.1111/j.1572-0241.2003.08728.x 2 Malini Gupta-Ganguli, Kyle Cox, Blake Means, Ivan Gerling, Solomon S. Solomon; Does Therapy With Anti–TNF-α Improve Glucose Tolerance and Control in Patients With Type 2 Diabetes?. Diabetes Care 1 July 2011; 34 (7): e121–121. https://doi.org/10.2337/dc10-1334
P0812: Establishing a target dysplasia detection rate (DDR) as a quality metric for Inflammatory Bowel Disease surveillance.ECCO'25Year: 2025
Authors: Picardo, S.(1,2)*;Baker, J.(1);Geow, R.(3);Halpin, S.(1);Cheng, W.(1);Ragunath, K.(1,2);
(1)Royal Perth Hospital, Gastroenterology and Hepatology, Perth, Australia;(2)Curtin University, Department of Medicine, Perth, Australia;(3)University of Western Australia, Department of Medicine, Perth, Australia;
P0813: Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitisECCO'25Year: 2025
Authors: Vermeire, S.(1)*;Peyrin-Biroulet, L.(2);Danese, S.(3);Dubinsky, M.(4);Dulai, P.S.(5);Tilg, H.(6);Siegmund, B.(7);Hisamatsu, T.(8);Shan, K.(9);Jacobstein, D.(10);Cataldi, F.(11);Rabbat, C.(11);Sands, B.E.(12);
(1)University hospitals Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;(2)INFINY Institute- INSERM NGERE- CHRU Nancy, Department of Gastroenterology, Vandœuvre-lès-Nancy, France;(3)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, San Raffaele, Italy;(4)Mount Sinai Kravis Children’s Hospital, Pediatric GI and Nutrition, New York, United States;(5)Feinberg School of Medicine Northwestern University, Gastroenterology and Hepatology, Chicago, United States;(6)Medical University, Department of Gastroenterology- Hepatology- Endocrinology & Metabolism, Innsbruck, Austria;(7)Charité Universitätsmedizin, Department of Gastroenterology- Infectious Diseases and Rheumatology, Berlin, Germany;(8)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(9)Abivax, Biometrics, Paris, France;(10)Abivax, Clinical Development, Paris, France;(11)Abivax, Medical Affairs, Paris, France;(12)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;
1. Vermeire S, et al. J Crohns Colitis. 2023; 17: 1689-1697
2. Vermeire S, et al. Gastroenterology 2021; 160: 2595-2598
3. Vermeire S, et al. The Lancet Gastroenterology & Hepatology. 2022; 7: 1024-1035.
P0814: Transmural healing in Crohn’s disease: Real-world insights from the SUNRISE study on vedolizumab using intestinal ultrasonographyECCO'25Year: 2025
Authors: Carter, D.(1)*;Fiorino, G.(2);Biedermann, P.(3);Cassanelli, F.(4);Meyer, M.(5);Novak, K.L.(6);Kopylov, U.(1);
(1)Sheba Medical Center- School of Medicine- Tel Aviv University, Department of Gastroenterology, Tel Aviv, Israel;(2)A.O. San Camillo-Forlanini, IBD Unit- Department of Gastroenterology and Digestive Endoscopy, Rome, Italy;(3)Takeda Pharmaceuticals International AG, Global Medical Evidence, Zurich, Switzerland;(4)IQVIA Solutions Italy s.r.l., Real World Solutions, Modena, Italy;(5)Takeda Pharma AG, Medical Affairs, Zurich, Switzerland;(6)University of Calgary, Division of Gastroenterology and Hepatology- Department of Medicine, Calgary AB, Canada;
1. Ilvemark J.F.K.F. et al. J Crohns Colitis 2022;16:554–80.
2. Turner D. et al.Gastroenterol 2021;160:1570–83.
P0815: Oral alpha 4 beta 7 (α4β7) integrin antagonist EA1080 (NSHO-101) demonstrates target engagement and α4β7 integrin receptor occupancy following once-daily administration in healthy volunteersECCO'25Year: 2025
Authors: Feagan, B.G.(1)*;Yazawa, Y.(2);Seki, T.(3);Watanabe, E.(2);Ohishi, H.(2);Ueo, H.(4);Saito, C.(5);Lorch, U.(6);
(1)Western University, Division of Gastroenterology- Department of Medicine, London, Canada;(2)EA Pharma Co.- Ltd., Clinical Development Group- Pharmaceutical Development Dept.- Research and Development HQ, Tokyo, Japan;(3)EA Pharma Co.- Ltd., Strategic Business Development & Alliance- Corporate Strategy HQ, Tokyo, Japan;(4)EA Pharma Co.- Ltd., Human Translational Research Group- Pharmaceutical Development Dept.- Research and Development HQ, Tokyo, Japan;(5)EA Pharma Co.- Ltd., Pharmaceutical Development Dept.- Research and Development HQ, Tokyo, Japan;(6)Richmond Pharmacology, Clinical Trial Design and Methodology, London, United Kingdom;
P0816: Dietary habits of ulcerative colitis patients under follow-up in a Pediatric Inflammatory Bowel Disease UnitECCO'25Year: 2025
Authors: Herrador Lopez, M.(1)*;Martín-Masot, R.(2);Sarbagilli, C.(3);Navas-López, V.M.(2);
(1)Hospital Materno-Infantil. Hospital Regional Universitario de Málaga, Pediatric Gastroenterology and Nutrition Unit, Málaga, Spain;(2)Hospital Materno Infantil. Hospital Regional Universitario de Málaga, Pediatric Gastroenterology and Nutrition Unit, Málaga, Spain;(3)The E. Wolfson Medical Center, Pediatric Gastroenterology and Nutrition Unit, Holon, Israel;
P0818: Addressing unmet needs in adult Inflammatory Bowel Disease careECCO'25Year: 2025
Authors: Playford, C.(1)*;Asghar, Z.(1);Armstrong, S.(2);Ngomba, R.(1);Rochford, A.(3);
(1)University of Lincoln, School of Health and Care Sciences, Lincoln, United Kingdom;(2)University of Lincoln, Research Impact and Culture, Lincoln, United Kingdom;(3)Royal Free London Hospitals NHS Foundation Trust, Gastroenterology, London, United Kingdom;
1. Miglioretto C, Beck E, Lambert K. What do people with inflammatory bowel disease want to know about diet? The dietary information needs of people with inflammatory bowel disease and perceptions of healthcare providers. J. Hum. Nutr. Diet. 2024; 37:706-716. DOI: 10.1111/jhn.13297.
2. NICE (2015) Inflammatory bowel disease. Quality standard. https://www.nice.org.uk/guidance/qs81/chapter/Quality-statement-2-Multidisciplinary-team-support (accessed 4 November 2024).
3. IBD UK (2021) Crohn’s and Colitis Care in the UK. The Hidden Cost and a Vision for Change. https://crohnsandcolitis.org.uk/media/k01ojh41/ibd-national-report.pdf (accessed 04 November 2024).
4. Regueiro M, Click B, Anderson A, et al. Reduced Unplanned Care and Disease Activity and Increased Quality of Life After Patient Enrollment in an Inflammatory Bowel Disease Medical Home.
Clin. Gastroenterol. Hepatol. 2018;
16: 1777-1785. DOI: 10.1016/j.cgh.2018.04.007.
P0819: AIRIS-Crohn: Results on the Effectiveness and Safety of Risankizumab in the Medium Term in Real-World Clinical Practice.ECCO'25Year: 2025
Authors: Caballero Mateos, A.M.(1)*;Olmedo Martín, R.V.(2);Gijón-Villanova, R.(1);Gutiérrez-Holanda, C.(1);Fernández-Moreno, N.(3);Martín-Rodríguez, M.D.M.(4);Silva-Albarellos, E.(5);Rodríguez-González, F.J.(6);Hernández-Martínez, Á.(7);Benítez, J.M.(8);Mata, F.J.(9);Trapero-Martínez, A.M.(10);Valdés-Delgado, T.(5);
(1)San Cecilio University Hospital, Gastroenterology, Granada, Spain;(2)Hospital Regional, Gastroenterology, Málaga, Spain;(3)Costal del Sol Hospital, Gastroenterology, Marbella, Spain;(4)Virgen de las Nieves University Hospital, Gastroenterology, Granada, Spain;(5)Virgen Macarena University Hospital, Gastroenterology, Seville, Spain;(6)Virgen de la Victoria University Hospital, Gastroenterology, Málaga, Spain;(7)Torrecárdenas University Hospital, Gastroenterology, Almería, Spain;(8)Reina Sofía University Hospital, Gastroenterology, Córdoba, Spain;(9)Puerto Real Hospital, Gastroenterology, Puerto Real, Spain;(10)University Hospital of Jaén, Gastroenterology, Jaén, Spain; GATEII
1- de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017Dec;14(12):739–492- Ahmad T, Tamboli CP, Jewell D, Colombel JF. Clinical relevance of advances ingenetics and pharmacogeneticsof IBD. Gastroenterology. 2004 May;126(6):1533–49.3- Feuerstein JD, Cheifetz AS. Crohn Disease: Epidemiology, Diagnosis, andManagement. Mayo Clin Proc. 2017 Jul;92(7):1088-1103. doi:10.1016/j.mayocp.2017.04.010.4- Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, PeyrinBiroulet L, Danese S. Crohn's disease. Nat Rev Dis Primers. 2020 Apr 2;6(1):22. doi:10.1038/s41572-020-0156-2. Erratum in: Nat Rev Dis Primers. 2020 Apr 6;6(1):26. Erratum in: Nat Rev Dis Primers. 2020 May 20;6(1):42. Erratum in: Nat Rev Dis Primers. 2020 Jun 19;6(1):51. Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020 Sep 10;6(1):745- Flynn S, Eisenstein S. Inflammatory Bowel Disease Presentation and Diagnosis. SurgClin North Am. 2019 Dec;99(6):1051-1062. doi: 10.1016/j.suc.2019.08.001. Epub 2019Sep 11. PMID: 31676047.6- Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, andtreatment methods of inflammatory bowel disease. J Med Life. 2019 Apr-Jun;12(2):113-122. doi: 10.25122/jml-2018-0075. PMID: 31406511; PMCID: PMC6685307.
7- Loftus EV Jr, Panés J, Lacerda AP, Peyrin-Biroulet L, D'Haens G, Panaccione R,Reinisch W, Louis E, Chen M, Nakase H, Begun J, Boland BS, Phillips C, Mohamed MF, Liu J, Geng Z, Feng T, Dubcenco E, Colombel JF. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2023 May 25;388(21):1966-1980. doi: 10.1056/NEJMoa2212728
8. D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M,Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. Risankizumab as induction therapy for Crohn's disease: results from thephase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 May28;399(10340):2015-2030.doi: 10.1016/S0140-6736(22)00467-6. PMID: 35644154.10- Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M,Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y,Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K,D'Haens G. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebocontrolled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022 May28;399(10340):2031-2046.doi: 10.1016/S0140-6736(22)00466-4. PMID: 35644155.
P0820: Video-assisted anal fistula treatment (VAAFT) in Crohn´s perianal disease: a Brazilian single-center prospective cohort studyECCO'25Year: 2025
Authors: Gardere Camergo, M.(1)*;Vital Pinheiro Saito, L.(1);Natali Moraes, P.(1);Minatel Vidal de Negreiros, L.(1);Nunes Angelo, S.(1);Real Martinez, C.A.(1);Oliveira Magro, D.(2);Saddy Rodrigues Coy, C.(1);
(1)Clinica Coy, Colorectal Surgery, Campinas, Brazil;(2)Clínica Coy, Colorectal Surgery, Campinas, Brazil;
P0821: Effectiveness and safety of mesenchymal stem cell treatment in fistulizing Crohn’s disease: predictors of treatment successECCO'25Year: 2025
Authors: Bacsur, P.(1,2)*;Shaham, D.(3);Serclova, Z.(4,5);Resál, T.(1);Farkas, B.(1);Sarlós, P.(6);Miheller, P.(7);Maharshak, N.(3);Zemel, M.(8);Shirit, A.(9);Bálint, A.(1);Fábián, A.(1);Bor, R.(1);Bősze, Z.(1);Ivány, E.(1);Szepes, Z.(1);Farkas, K.(1,2);Tóth, I.(10);Lázár, G.(10);Vlkova, K.(4);Tremerova, A.(4);Zuskova, P.(11);Ábrahám, S.(10);Molnár, T.(1);
(1)Albert Szent-Györgyi Medical School- University of Szeged, Department of Medicine, Szeged, Hungary;(2)HCEMM-USZ, Translational Colorectal Research Group, Szeged, Hungary;(3)Faculty of Medical and Health Sciences- Tel Aviv University, IBD Unit- Tel Aviv Medical Center, Tel Aviv, Israel;(4)Clinical IBD Center ISCARE, Surgical Department, Prague, Czech Republic;(5)University Hospital Kralovske Vinohrady, Surgical Department, Prague, Czech Republic;(6)Medical School- University of Pécs, Division of Gastroenterology- First Department of Medicine, Pécs, Hungary;(7)Faculty of Medicine- Semmelweis University, Department of Surgery- Transplantation and Gastroenterology, Budapest, Hungary;(8)Tel Aviv Medical Center- Faculty of Medicine- Tel Aviv University, Colorectal Unit- Surgical Division, Tel Aviv, Israel;(9)Shaare Zedek Medical Center- Hebrew University, Digestive Diseases Institute - IBD-MOM Unit, Jerusalem, Israel;(10)Albert Szent-Györgyi Medical School- University of Szeged, Department of Surgery, Szeged, Hungary;(11)Clinical IBD Center ISCARE, Surgical Department- Prague- Czech Republic, Prague, Czech Republic;
P0822: Comparative Effectiveness and Safety of Upadacitinib and Vedolizumab in Anti-TNF Experienced Patients with Ulcerative Colitis: A Retrospective StudyECCO'25Year: 2025
Authors: Sror, N.(1)*;Leibovitzh, H.(2);Hirsch, A.(2);Thurm, T.(2);Ron, Y.(2);Maharshak, N.(2);Cohen, N.A.(2);
(1)Department of Internal Medicine B- Tel Aviv Sourasky Medical Center, Faculty of Medicine- Tel Aviv University- Tel Aviv- Israel, Tel Aviv, Israel;(2)IBD Unit- Tel Aviv Sourasky Medical Center- Tel Aviv- Israel, Faculty of Medicine- Tel Aviv University- Tel Aviv- Israel, Tel Aviv, Israel;
P0823: Access to an integrated Inflammatory Bowel Disease diet clinic improves patient-reported outcomes and dietary self-confidence in a tertiary service previously without dietetic servicesECCO'25Year: 2025
Authors: Day, A.(1,2,3)*;Chu, M.(1,4);Scinto, T.(2);Han, S.(1);Vinci, I.(1);Hatzi, M.(2);Bryant, R.(1,5);
(1)The Queen Elizabeth Hospital, Gastroenterology, Woodville South- Adelaide, Australia;(2)The Queen Elizabeth Hospital, Nutrition and Dietetics, Woodville South- Adelaide, Australia;(3)Basil Hetzel Institute, Inflammatory Bowel Disease Research Group, Adelaide, Australia;(4)University of Adelaide, School of Health and Medical Sciences, Adelaide, Australia;(5)Basil Hetzel Institute, Inflammatory Bowel Disease Research Group, Woodville South- Adelaide, Australia; Inflammatory Bowel Disease Research Group
P0824: Patient-Reported Outcomes in Chinese Patients with Inflammatory Bowel Disease treated with Vedolizumab: A subgroup analysis of second interim analysis of VALUE studyECCO'25Year: 2025
Authors: Gao, X.(1);Ge, W.(2);Yu, J.(3);Wang, X.(4);Feng, X.(5);Qian, X.(6);Gu, L.(7);Chen, M.(8)*;
(1)The Sixth Affiliated Hospital- Sun Yet-sen University, Gastroenterology Department, Guangzhou, China;(2)Xinhua Hospital- School of Medicine- Shanghai Jiao Tong University, Gastroenterology Department, Shanghai, China;(3)The First Affiliated Hospital of Shantou University Medical College, Gastroenterology Department, Shantou, China;(4)The Third Xiangya Hospital of Centre South University, Gastroenterology Department, Changsha, China;(5)The Second Affiliated Hospital of Dalian Medical University, Gastroenterology Department, Dalian, China;(6)Takeda China International Trade Co.- Ltd- Shanghai- China- 200127, China Medical Team, Nanjing, China;(7)Takeda China International Trade Co.- Ltd-, China Medical Team, Shanghai, China;(8)The First Affiliated Hospital- Sun Yat-Sen University, Gastroenterology Department, Guangzhou, China;
